A Phase 2 interventional study of Vadadustat in Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-06-28.
Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing vadadustat in Renal Insufficiency, Chronic — none open to participants now, none under way, none of them phase 3. vadadustat · Renal Insufficiency, Chronic.
Among the 18 studies testing vadadustat in Renal Insufficiency, Chronic, this one is the 13th largest by enrollment, is one of 2 that started in 2010, is one of 6 in phase 2, and was the 14th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 18 studies testing vadadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2010.
This study's enrollment of 22 is below the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 94 across the 18 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 1 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
24 studies in Renal Insufficiency, Chronic by Akebia Therapeutics: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 24 studies in Renal Insufficiency, Chronic by Akebia Therapeutics, this one is the 19th largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 2, and was the 19th registered.
Akebia Therapeutics’s Renal Insufficiency, Chronic studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing vadadustat in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Akebia Therapeutics’s 24 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose of Vadadustat.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate \[eGFR\] 30 - 59 milliliters \[mL\]/minute) received a single 500 milligram (mg) oral dose of Vadadustat after fasting for at least 4 hours.
Drug: Vadadustat
Participants with Stage 4 CKD (eGFR \<30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of Vadadustat after fasting for at least 4 hours.
Drug: Vadadustat
oral capsules
Also known as: AKB-6548
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An Adverse Event (AE) was defined as any untoward, undesired, unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study following study medication administration, regardless of causal relationship. This also included any clinically significant worsening or re-occurrence of a pre-existing condition, or AE occurring from an overdose of a study drug whether accidental or intentional or AE occurring from abuse of study drug or that has been associated with the discontinuation of the use of study drug.
Time frame: Up to Day 8
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to Day 8
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes. Number of participants with a clinically significant change from baseline in at least one of the assessed vital signs parameters is reported.
Time frame: Up to Day 8
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.
Time frame: Up to Day 2
Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected). The baseline was defined as Day 1 pre-dose measurement. If missing, the last measurement prior to dosing was used.
Time frame: Baseline; Day 2
Change From Baseline in Heart Rate
The heart rate evaluation was performed after the participant had been resting comfortably in a supine position for approximately 10 minutes.
Time frame: Baseline; Day 2
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings
A baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to Day 8
Geometric Mean Maximum Observed Plasma Concentration (Cmax) of AKB-6548
Plasma samples were collected from the participants at the defined time points. Cmax was defined as the maximum observed plasma concentration. Cmax was calculated using the standard non-compartmental method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Median Time to Reach Cmax (Tmax) of AKB-6548
Plasma samples were collected from the participants at the defined time points. Tmax was defined as the time to reach maximum plasma concentration. Tmax was calculated using the standard non-compartmental method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Mean Terminal Elimination Rate Constant (λz)
Plasma samples were collected from the participants at the defined time points. λz was calculated using linear regression of the terminal linear portion of the log concentration vs. time curve. The parameter was calculated by linear least-squares regression analysis using three or more concentrations, excluding Cmax.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Median Terminal Elimination Half-life (T½)
Plasma samples were collected from the participants at the defined time points. T½ was defined as apparent terminal elimination half-life. T½ was calculated using the standard non-compartmental method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Geometric Mean Area Under the Plasma Concentration-time Curve From 0 to Time T Over a Dosing Interval (AUC[0-T])
Plasma samples were collected from the participants at the defined time points. AUC\[0-T) was defined as the area under the plasma concentration-time curve, from time=0 to the last measurable concentration (Ct) up to 24 hours, calculated by the linear trapezoidal method. AUC\[0-T) was calculated using the standard noncompartmental method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Geometric Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-∞])
Plasma samples were collected from the participants at the defined time points. AUC\[0-∞\] was defined as the area under the plasma concentration-time curve from time=0 and extrapolated to infinity. AUC\[0-∞\] was calculated using the standard non-compartmental method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Geometric Mean Apparent Oral Clearance (CL/F)
Plasma samples were collected from the participants at the defined time points. CL/F was defined as apparent oral clearance, calculated as Dose/AUC(0-inf). CL/F was calculated using the standard non-compartmental method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Geometric Mean Apparent Volume of Distribution During the Terminal Phase (Vd/F)
Plasma samples were collected from the participants at the defined time points. Vd/F was defined as the apparent volume of distribution during the terminal phase, calculated as Dose/\[λz \* AUC(0-inf)\]. Vd/F was calculated using the standard non-compartmental method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Change From Baseline in Mean Erythropoietin (EPO)
The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
Time frame: Baseline; 8, 12, and 24 hours post-dose
Exploratory: Change From Baseline in Hepcidin at 24 Hours
Time frame: Baseline; 24 hours post-dose
Exploratory: Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at 24 Hours
Time frame: Baseline; 24 hours post-dose
Exploratory: Change From Baseline in Transferrin at 24 Hours
Time frame: Baseline; 24 hours post-dose
Exploratory: Change From Baseline in Cystatin-C at 24 Hours
Time frame: Baseline; 24 hours post -dose
Exploratory: Change From Baseline in Adiponectin at 24 Hours
Time frame: Baseline; 24 hours post -dose
Exploratory: Change From Baseline in Ferritin at 24 Hours
Time frame: Baseline; 24 hours post-dose
| Milestone | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Started | 10 | 12 |
| Completed | 10 | 12 |
| Not completed | 0 | 0 |
An Adverse Event (AE) was defined as any untoward, undesired, unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study following study medication administration, regardless of causal relationship. This also included any clinically significant worsening or re-occurrence of a pre-existing condition, or AE occurring from an overdose of a study drug whether accidental or intentional or AE occurring from abuse of study drug or that has been associated with the discontinuation of the use of study drug.
| Participants | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 6 | 2 |
Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Urinalysis | 0 | 0 |
| Hematology | 0 | 0 |
| Serum chemistry | 1 | 0 |
| Coagulation | 0 | 0 |
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes. Number of participants with a clinically significant change from baseline in at least one of the assessed vital signs parameters is reported.
| Participants | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values | 2 | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.
| Participants | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings | 0 | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected). The baseline was defined as Day 1 pre-dose measurement. If missing, the last measurement prior to dosing was used.
| Milliseconds | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Baseline PR interval | 178.8 ± 44.2 | 182.5 ± 24.2 |
| Change from Baseline at Day 2 PR interval | -12.4 ± 28.4 | -3.5 ± 5.5 |
| Baseline QRS interval | 98.8 ± 20.7 | 97.7 ± 26.0 |
| Change from Baseline at Day 2 QRS interval | -0.8 ± 3.2 | 0.0 ± 5.4 |
| Baseline QT interval | 427.2 ± 22.0 | 426.5 ± 39.7 |
| Change from Baseline at Day 2 QT interval | -13.8 ± 21.8 | -2.3 ± 16.7 |
| Baseline QTc interval | 423.5 ± 22.8 | 439.5 ± 35.8 |
| Change from Baseline at Day 2 QTc interval | 3.1 ± 10.2 | 2.0 ± 18.2 |
The heart rate evaluation was performed after the participant had been resting comfortably in a supine position for approximately 10 minutes.
| Beats per minute | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Baseline | 59.8 ± 9.0 | 64.3 ± 5.6 |
| Change from Baseline at Day 2 | 5.2 ± 6.3 | 1.8 ± 3.7 |
A baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings | 0 | 0 |
Plasma samples were collected from the participants at the defined time points. Cmax was defined as the maximum observed plasma concentration. Cmax was calculated using the standard non-compartmental method.
| Micrograms per millilitre (mcg/mL) | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Geometric Mean Maximum Observed Plasma Concentration (Cmax) of AKB-6548 | 42.486 ± 36.314 | 40.952 ± 35.022 |
Plasma samples were collected from the participants at the defined time points. Tmax was defined as the time to reach maximum plasma concentration. Tmax was calculated using the standard non-compartmental method.
| Hours | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Median Time to Reach Cmax (Tmax) of AKB-6548 | 5.5 (1.0 to 8.0) | 5.0 (2.0 to 6.0) |
Plasma samples were collected from the participants at the defined time points. λz was calculated using linear regression of the terminal linear portion of the log concentration vs. time curve. The parameter was calculated by linear least-squares regression analysis using three or more concentrations, excluding Cmax.
| 1/Hour | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Mean Terminal Elimination Rate Constant (λz) | 0.105 ± 0.029 | 0.086 ± 0.020 |
Plasma samples were collected from the participants at the defined time points. T½ was defined as apparent terminal elimination half-life. T½ was calculated using the standard non-compartmental method.
| Hours | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Median Terminal Elimination Half-life (T½) | 7.070 (4.530 to 9.930) | 7.530 (5.680 to 12.270) |
Plasma samples were collected from the participants at the defined time points. AUC\[0-T) was defined as the area under the plasma concentration-time curve, from time=0 to the last measurable concentration (Ct) up to 24 hours, calculated by the linear trapezoidal method. AUC\[0-T) was calculated using the standard noncompartmental method.
| mcg*hr/mL | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Geometric Mean Area Under the Plasma Concentration-time Curve From 0 to Time T Over a Dosing Interval (AUC[0-T]) | 441.651 ± 36.162 | 448.399 ± 34.081 |
Plasma samples were collected from the participants at the defined time points. AUC\[0-∞\] was defined as the area under the plasma concentration-time curve from time=0 and extrapolated to infinity. AUC\[0-∞\] was calculated using the standard non-compartmental method.
| mcg*hr/mL | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Geometric Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-∞]) | 503.688 ± 41.671 | 535.813 ± 40.320 |
Plasma samples were collected from the participants at the defined time points. CL/F was defined as apparent oral clearance, calculated as Dose/AUC(0-inf). CL/F was calculated using the standard non-compartmental method.
| Litre per Hour (L/hr) | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Geometric Mean Apparent Oral Clearance (CL/F) | 0.995 ± 41.683 | 0.934 ± 40.324 |
Plasma samples were collected from the participants at the defined time points. Vd/F was defined as the apparent volume of distribution during the terminal phase, calculated as Dose/\[λz \* AUC(0-inf)\]. Vd/F was calculated using the standard non-compartmental method.
| Liter | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Geometric Mean Apparent Volume of Distribution During the Terminal Phase (Vd/F) | 9.863 ± 20.479 | 11.105 ± 31.747 |
The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
| milli-international units per milliliter | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| Baseline | 23.14 ± 15.00 | 21.65 ± 15.84 |
| 8 Hours Post-dose | 6.16 ± 9.97 | 12.07 ± 11.13 |
| 12 Hours Post-dose | 5.41 ± 7.66 | 11.09 ± 8.71 |
| 24 Hours Post-dose | -1.44 ± 5.71 | 2.08 ± 5.57 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to Day 8. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: CKD Stage 3 Vadadustat | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Cohort 2: CKD Stage 4 Vadadustat | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Event | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat |
|---|---|---|
| NauseaGastrointestinal disorders | 2/10 | 0/12 |
| TachycardiaCardiac disorders | 1/10 | 0/12 |
| VomitingGastrointestinal disorders | 1/10 | 0/12 |
| PyrexiaGeneral disorders | 1/10 | 0/12 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/10 | 0/12 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/10 | 0/12 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/10 | 0/12 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 1/10 | 0/12 |
| Skin PapillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 | 0/12 |
| HeadacheNervous system disorders | 1/10 | 0/12 |
Enrolled Population: The enrolled population consisted of all participants who were enrolled in the study.
| Age, Continuous(years) | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat | Total |
|---|---|---|---|
| Mean | 63.0 ± 12.9 | 64.4 ± 10.0 | 63.8 ± 11.1 |
| Sex: Female, Male(Participants) | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat | Total |
|---|---|---|---|
| Female | 5 | 8 | 13 |
| Male | 5 | 4 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 12 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 9 | 11 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Estimated Glomerular Filtration Rate(mL/min/1.73m^2) | Cohort 1: CKD Stage 3 Vadadustat | Cohort 2: CKD Stage 4 Vadadustat | Total |
|---|---|---|---|
| Mean | 45.22 ± 8.54 | 24.39 ± 3.31 | 33.86 ± 12.23 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2010 to primary completion in Sep 2010, 2 months.
Results were first posted in May 2022, 11 years 7 months after primary completion. A results delay was requested in Jan 2021.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 2 months is below that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat
Renal Insufficiency, Chronic →